Last 47 quarters of trend data · Healthcare · Immunology Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -15.16 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 13.73 | 5.11 | 6.12 | 5.47 | 10.03 | 8.51 | 3.88 | 4.85 | 11.23 | 28.38 | 2.12 | 2.62 | 2.23 | 1.61 | 2.20 | 0.87 | 0.71 | 0.59 | 0.57 | 0.85 | 1.15 |
| — | -39.9% | +57.9% | +12.9% | -10.6% | -70.0% | +82.8% | +85.2% | +403.2% | +1658.1% | -3.5% | +201.8% | +216.4% | +173.9% | +283.4% | +1.9% | -38.9% | -70.9% | -51.0% | -24.4% | -20.9% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | 3.87 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -32.6% | -9.4% | -7.7% | -9.1% | -18.5% | -13.4% | -12.3% | 37.1% | -53.9% | -126.4% | -10.1% | -15.8% | -16.0% | -12.8% | -13.2% | -15.0% | -16.3% | -20.4% | -9.8% | -8.9% | -9.1% |
| — | +29.8% | +37.6% | -124.4% | +65.6% | +89.4% | -22.5% | +334.5% | -235.9% | -887.7% | +23.8% | -5.5% | +1.3% | +37.4% | -34.5% | -68.9% | -78.0% | -93.1% | +20.2% | +36.2% | -119.1% | |
| ROA | -21.8% | -8.8% | -7.3% | -8.4% | -16.3% | -12.0% | -10.7% | 23.7% | -19.0% | -65.2% | -8.1% | -13.3% | -13.6% | -10.9% | -11.2% | -12.5% | -13.2% | -17.2% | -8.6% | -7.9% | -8.1% |
| — | +26.5% | +32.1% | -135.7% | +14.3% | +81.7% | -31.9% | +277.8% | -39.0% | -497.5% | +27.2% | -6.9% | -3.3% | +36.4% | -29.7% | -58.2% | -63.6% | -83.8% | +19.7% | +33.8% | -120.9% | |
| ROIC | -78.1% | -8.0% | -7.1% | -8.6% | -14.4% | -11.6% | -13.7% | -21.1% | -36.8% | -24.1% | -13.9% | -17.2% | -15.9% | -12.0% | -9.9% | -11.3% | -9.6% | -19.1% | -9.0% | -11.2% | -13.8% |
| — | +31.2% | +48.4% | +59.2% | +60.9% | +51.8% | +1.3% | -22.5% | -131.5% | -101.4% | -40.7% | -52.3% | -65.6% | +37.3% | -9.6% | -0.8% | +30.4% | -6.9% | +51.8% | +28.7% | +25.6% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.00 | 0.00 | 0.00 | 0.02 | 0.01 | 0.01 | 0.02 | 0.03 | 0.03 | 0.01 | 0.03 | 0.04 | 0.04 | 0.04 | 0.05 | 0.05 | 0.04 | 0.04 | 0.04 | 0.04 |
| — | -78.5% | -76.1% | -85.2% | -55.6% | -50.6% | -1.2% | -25.0% | -3.0% | -25.2% | -66.2% | -33.9% | -23.4% | -14.0% | +3.6% | +24.6% | +23.5% | +20.1% | +110.7% | +74.1% | +17.2% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 6.21 | 13.16 | 16.16 | 19.81 | 6.21 | 8.29 | 8.91 | 4.90 | 1.54 | 0.92 | 3.62 | 3.40 | 4.07 | 4.53 | 4.82 | 4.29 | 4.06 | 3.67 | 5.80 | 6.95 | 7.36 |
| — | +58.8% | +81.4% | +304.2% | +303.8% | +796.5% | +146.2% | +44.2% | -62.2% | -79.6% | -25.0% | -20.7% | +0.2% | +23.6% | -16.8% | -38.3% | -44.8% | -47.3% | +3.7% | +40.5% | +97.2% | |
| Quick Ratio | 6.21 | 13.16 | 16.16 | 19.81 | 6.21 | 8.29 | 8.91 | 4.90 | 1.54 | 0.92 | 3.62 | 3.40 | 4.07 | 4.53 | 4.82 | 4.29 | 4.06 | 3.67 | 5.80 | 6.95 | 7.36 |
| — | +58.8% | +81.4% | +304.2% | +303.8% | +796.5% | +146.2% | +44.2% | -62.2% | -79.6% | -25.0% | -20.7% | +0.2% | +23.6% | -16.8% | -38.3% | -44.8% | -47.3% | +3.7% | +40.5% | +97.2% | |
| Interest Coverage | — | -11.18 | — | -6.67 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -1153.50 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CRVS stock.
Corvus Pharmaceuticals, Inc.'s current P/E is -15.2x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Corvus Pharmaceuticals, Inc.'s business trajectory between earnings reports.